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SUMMARY
Schistosomiasis and food-borne trematodiases are chronic parasitic diseases aﬀecting millions of people mostly in the
developing world. Additional drugs should be developed as only few drugs are available for treatment and drug resistance
might emerge. In vitro and in vivo whole parasite screens represent essential components of the trematodicidal drug
discovery cascade. This review describes the current state-of-the-art of in vitro and in vivo screening systems of the blood
ﬂukeSchistosoma mansoni, the liver ﬂukeFasciola hepatica and the intestinal ﬂukeEchinostoma caproni. Examples of in vitro
and in vivo evaluation of compounds for activity are presented. To boost the discovery pipeline for these diseases there is a
need to develop validated, robust high-throughput in vitro systems with simple readouts.
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INTRODUCTION
Thus far approximately 6000 species in the sub-class
Digenea, phylum Platyhelminthes have been de-
scribed in the literature. Among them, only a dozen
or so species parasitize humans. These include
the blood ﬂukes (ﬁve species of Schistosoma), liver
ﬂukes (Clonorchis sinensis,Fasciola gigantica,Fasciola
hepatica, Opisthorchis felineus and Opisthorchis
viverrini), lung ﬂukes (Paragonimus spp.) and intes-
tinal ﬂukes (e.g. Echinostoma spp. and Fasciolopsis
buski) (Cox, 1993;Keiser andUtzinger, 2009). These
parasites are the causative agents of a complex of
some acute, but mainly chronic infections: schisto-
somiasis and food-borne trematodiases (Keiser and
Utzinger, 2007; Utzinger et al. 2007; Davis, 2009;
Sithiathaworn et al. 2009). It is currently estimated
that 1400 million people are at risk of schistosomiasis
and food-borne trematodiases with more than 250
million infections (Keiser and Utzinger, 2005;
Steinmann et al. 2006). Whilst the global burden of
schistosomiasis has been estimated at 1.7–4.5 million
disability-adjusted life years (Utzinger and Keiser,
2004; Hotez et al. 2009), that of food-borne trema-
todiases remains to be investigated (Keiser and
Utzinger, 2009). Schistosomiasis and food-borne
trematodiases belong to the so-called neglected
tropical diseases (Hotez et al. 2009; Keiser and
Utzinger, 2009). The global strategy for the control
of schistosomiasis and food-borne trematodiases and
other parasitic worm infections is morbidity control
by chemotherapy. However, only two drugs are
currently available: triclabendazole against fascio-
liasis and praziquantel against the other food-borne
trematode infections and schistosomiasis (Keiser and
Utzinger, 2004; Keiser et al. 2005). Hence, there is a
need for discovery and development of new drugs,
particularly in view of growing concern about re-
sistance developing to existing drugs. Triclabend-
azole resistance is already common in veterinary
parasitology (Keiser et al. 2005) and the extensive use
of praziquantel resistance in mass drug adminis-
tration programs has raised concern regarding the
selection of drug resistant schistosomes (Melmann
et al. 2009).
There has been little incentive to invest in the
discovery and development of trematodicidal drugs.
While public-private partnerships have been formed
for some of the neglected tropical diseases (e.g. the
Drugs for Neglected Diseases Initiative (DNDi)
focusing on human African trypanosomiasis and
leishmaniasis), devoted drug discovery and devel-
opment programmes do not yet exist for any of the
major helminth diseases (Ridley and Kita, 2007).
Moreover, funding for basic research on these para-
sites and the pathogenesis of neglected tropical dis-
eases has been inadequate (Renslo and McKerrow,
2006). To date, in vitro cultivation of trematodes
lags behind the cultivation of protozoa or bacteria
and cultivation throughout the entire life cycle is not
possible (Smyth and Halton, 1983). Additionally,
only very few digeneans are maintained in the lab-
oratory, primarily due to their complex life cycles.
Life cycles requiring at least 2 hosts, a vertebrate
and a molluscan host, are the rule among digeneans
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(Cox, 1993; Gryseels et al. 2006; Keiser and
Utzinger, 2009). Finally, though target-based tre-
matodicidal drug discovery is starting to bear fruit
(Caﬀrey, 2007; Sayed et al. 2008; Abdulla et al.
2009), translation of targets identiﬁed through com-
parative genome searches and microarray analysis
into validated targets will require substantial econ-
omic eﬀorts (Renslo and McKerrow, 2006).
In the present article, I review in vitro and in vivo
trematode models available for chemotherapeutic
studies. Emphasis is placed on screening against
whole parasites since a molecular-target approach is
still rarely employed in trematodicidal drug dis-
covery. The focus is on a blood ﬂuke (Schistosoma
mansoni), a liver ﬂuke (Fasciola hepatica) and an in-
testinal ﬂuke (Echinostoma caproni). While S. man-
soni and F. hepatica are major human pathogens,
E. caproni is a rodent and avian ﬂuke, which is widely
and eﬀectively used as a laboratory model. Examples
of in vitro and in vivo evaluation of compounds
for activity against these three selected ﬂukes are
given. I conclude that for better targeted future
trematodicidal drug discovery there is a strong need
to develop validated, robust high-throughput in vitro
systems with simple readouts.
SCHISTOSOMA MANSONI
S. mansoni is an important model to study
schistosomiasis
S. mansoni is the most widely used schistosome
model, and its life cycle is kept in many institutions
worldwide. Fig. 1 summarizes laboratories in
Europe, USA, South America, Asia and Northern
Africa, which currently maintain the life cycle of
S. mansoni. Several of these laboratories such as
the Schistosomiasis Resource Center (Biomedical
Research Institute; Bethesda, USA) or the Theodor
Bilharz Research Institute, Giza, Egypt also provide
schistosome material for research or teaching pur-
poses. Remarkably, our search did not identify any
laboratories in sub-Saharan Africa (the area con-
sidered to be most severely aﬀected by schistosome-
induced morbidity (van der Werf et al. 2003), which
maintain the complete laboratory life-cycle of
S. mansoni.
Brieﬂy, in the deﬁnitive host S. mansoni worms
develop from a post-penetration larval stage, the
schistosomulum. The female worms produce eggs
which leave the body in excreta – faeces in the case of
S. mansoni, and on contact of the eggs with fresh
water free-swimming miracidia hatch out and infect
snails. For laboratory culture miracidia are hatched
from S. mansoni eggs taken from experimental
animal livers and/or intestines and Biomphalaria
glabrata is the intermediate host snail species most
commonly used (Fig. 2). Following asexual repro-
duction in the snails, cercariae are shed from the
snails into freshwater (Lewis, 2001).
S. haematobium is much less studied, as it is diﬃ-
cult to grow in rodents (Doenhoﬀ et al. 2009). To
my knowledge, the life cycle of S. haematobium
is currently maintained only in two laboratories,
namely the Theodor Bilharz Research Institute
(Giza, Egypt) and the Schistosomiasis Resource
Center. ‘Sibling’ species of S. haematobium, such as
S. bovis, S. matthei or S. margrebowiei, the life cycles
of which can be maintained in laboratory rodents,
might serve as models for S. haematobium (Agnew
et al. 1989).
S. japonicum, the third major human schistosome
species, is mainly studied in China. Nonetheless
several institutions outside China maintain the life
cycle and infected snails and mammals are also avail-
able on request from the Schistosomiasis Resource
Center. Though less frequently used, schistosome
species infecting other species of deﬁnitive hosts
might also prove useful for experimental studies: for
example, the bird schistosome Trichobilharzia ocel-
lata reaches oviposition after 9 days already and is
not pathogenic. Its life cycle has been described as
troublesome (Smyth and Halton, 1983).
S. mansoni in vitro assay based on schistosomula
Following the establishment of the S. mansoni life
cycle in the laboratory, in vitro parasite culture
techniques were developed (Ramirez et al. 2007).
Early work with schistosomula was based on the re-
covery of young worms from the lungs of infected
rodents, hence only limited worm material was
available (Smyth and Halton, 1983). The discovery
that schistosomula can be obtained by transforming
cercariae using simple techniques as centrifugation,
repeated aspiration through a syringe needle or
chemical stimulation was a breakthrough in the ﬁeld
of schistosome cultivation. Today cercariae are often
used as starting material for schistosome in vitro
studies as large numbers of schistosomula can be
obtained in a cost-eﬀective manner (Table 1, Fig. 2)
(Smyth and Halton, 1983; Abdulla et al. 2009;
Caﬀrey et al. 2009). In addition, most importantly,
the use of mechanically obtained schistosomula
reduces and replaces the use of live animals in
accordance with the 3Rs (reduce, replace, reﬁne)
of animal protection principles (Broadhead and
Bottrill, 1997). An assay with artiﬁcially produced
schistosomula might serve as a pre-screen in drug
sensitivity assays, however one has to keep in mind
that mechanically transformed schistosomula pos-
sess distinct diﬀerences to schistosomula, which
have penetrated the skin (e.g. biochemical diﬀer-
ences) or juvenile and adult schistosomes (Brink et al.
1977).
Several techniques for transforming cercariae and
maintaining schistosomula are available (Colley and
Wikel, 1974; Howells et al. 1974; Ramalho-Pinto
et al. 1974; Brink et al. 1977; Smyth and Halton,
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1983; Abdulla et al. 2009; Caﬀrey et al. 2009). In our
laboratories, for example, a Vortex transformation
method based on Ramalho-Pinto (Ramalho-Pinto
et al. 1974) is used. Brieﬂy, 50 ml of an ice-cold
cercarial suspension is centrifuged and the packed
cercariae are resuspended and vortexed for 2 min to
trigger tail loss. For the isolation of cercarial bodies
from tails, an ice-cold Hank’s basal salt solution
(HBSS) is added to the cercarial suspension and the
tail-rich supernatant is decanted (Manneck et al.
2009). Schistosomula are incubated in Basch
medium (Basch, 1981) supplemented with serum
and antibiotics or other culture media (Smyth and
Halton, 1983). Our own studies have shown that
schistosomula survive for at least 96 h in diﬀerent
media (Basch, MEM, DMEM or TC 199) regardless
of serum supplementation (author’s unpublished
observations). Abdulla and colleagues have recently
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Fig. 1. World map highlighting locations of laboratories, which maintain the life cycles of S. mansoni (circles),
F. hepatica (triangles) and E. caproni (squares). Laboratories were identiﬁed through contacting experts and literature
searches (using PubMed) restricted to the past 5 years.
Schistosoma mansoni : Aggeu Magalha˜es Institute (FIOCRUZ) (Recife, Brazil), Biomedical Research Institute
(Rockville, MD, USA), Butanta˜ Institute, Sa˜o Paulo (Sa˜o Paolo, Brazil), Catholic University of Rio Grande do Sul
(Porto Alegre, Brazil), CDC Atlanta (Atlanta, GA, USA), Chiang Mai University (Chiang Mai, Thailand),
DBL-Centre for Health Research and Development (Copenhagen, Denmark), Federal University of Rio de Janeiro
(Rio de Janeiro, Brazil), GIDE – Federal University of Minas Gerais (Belo Horizonte, Brazil), Gonc¸alo Muniz Institute
(FIOCRUZ) (Salvador, Brazil), Institut Pasteur de Lille (Lille, France), Instituto Rene´ Rachou-Fiocruz (Belo
Horizonte, Brazil), London School of Hygiene and Tropical Medicine (London, UK), Natural History Museum
(London, UK), National Research Council (Rome, Italy), Oswaldo Cruz Institute (FIOCRUZ) (Rio de Janeiro,
Brazil), Queensland Institute of Medical Research (Brisbane, Australia), Swiss Tropical Institute (Basel, Switzerland),
Theodor Bilharz Research Institute (Giza, Egypt), Trinity College (Dublin, Ireland), Tufts University (Boston, MA,
USA), Tulane University (New Orleans, LA. USA), Universidad San Pablo-CEU (Madrid, Spain), University
Erlangen-Nuremberg (Erlangen-Nuremberg, Germany), University New Mexico (Albuquerque, NM, USA),
University of Antwerp (Antwerp, Belgium), University of California San Francisco (San Francisco, USA), University
of Georgia (Athens, GA, USA), University of Heidelberg (Heidelberg, Germany), University of Melbourne
(Melbourne, Australia), University of Nottingham (Nottingham, UK), University of Occupational and Environmental
Health (Kitakyushu, Fukuoka, Japan), University of Sa˜o Paulo (Sa˜o Paolo, Brazil), University of Sa˜o Paulo, Ribeira˜o
Preto (Sa˜o Paolo, Brazil), University of Texas Health Science Center (San Antonio, TX, USA), University of the
Health Sciences (Bethesda, MD, USA), University of York (York, UK). Fasciola hepatica : Baldwin Aquatics
(Monmouth, OR, USA), Elizabeth Macarthur Agricultural Institute (Camden, Australia), Faculte´s de Me´decine et de
Pharmacie (Limoges, France), Queens University of Belfast (Belfast, Northern Ireland), Ridgeway Research Ltd
(Gloucestershire, UK), Veterinary Health Research (Armidale, NSW, Australia), Wageningen University
(Wageningen, Netherlands). Echinostoma caproni : Lafayette College (Easton, PA, USA), Swiss Tropical Institute
(Basel, Switzerland), Universidad de Valencia (Valencia, Spain), Universite´ de Perpignan (Perpignan, France),
University of Alberta (Alberta, Canada), University of California Santa Barbara (Santa Barbara, CA, USA).
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reported that schistosomula survive in Basch
medium for several weeks (Abdulla et al. 2009). In
Fig. 3a schistosomula incubated for 24 h in Basch
medium are shown. Fig. 3b depicts a scanning elec-
tron microscopic (SEM) image of a newly trans-
formed schistosomulum obtained by Vortex
transformation. Following incubation of schistoso-
mula with investigational drugs, changes in worm
motor activity, morphological/tegumental altera-
tions and occurrence of death are recorded at dif-
ferent time points. These phenotypic changes might
be scored using a viability scale from 0 to 3: (3=
totally vital, normally active, no morphological
changes, 2=slowed activity, ﬁrst morphological
changes and granularity visible, 1=minimal activity,
severe morphological changes and granularity, 0=all
worms dead, severe granularity) (Ramirez et al.
2007). For example, phenotypic changes following
praziquantel incubation (100 mg/ml) for 72 h can be
observed by means of light microscopy (Fig. 3c)
and SEM (Fig. 3d). Blebbing, furrows, swelling,
loss of structure and the lack of spines were visible
following incubation with praziquantel. Since the
assessment of morphological and behavioural re-
sponses of schistosomula to treatment is quite labour
intensive and time consuming, the use of a drug re-
sponse predictor (e.g. colourimetric assays, such as
MTT formazan (3-(4,5-dimethylthiazol 2-yl)-2,5-
diphenyltetrazolium formazan), which measures the
metabolic activity as a marker of viability in mam-
malian cell culture systems) should be explored. The
latter assay technology might oﬀer distinct ad-
vantages such as standardization, reproducibility and
accuracy and can be performed more rapidly and
easily, when compared to phenotypic evaluated drug
screens.
Adult S. mansoni in vitro assay
In parallel to the development of schistosomula
culture systems, culture methods for adult worms
have been established (Clegg, 1965; Ramirez et al.
2007). Today, in vitro chemotherapeutic studies
mainly rely on S. mansoni adults (Table 1, Fig. 2).
For example, standard operating procedures (SOPs)
for compound screening of the UNICEF/UNDP/
World Bank/WHO Special Programme for Research
and Training in Tropical Diseases (TDR) are based
on adult worms. Since the adult worm supply is
somewhat restricted, the in vitro throughput capacity
of this assay is limited (y2,000 compounds are
screened each year at TDR screening centers)
(Ramirez et al. 2007). For this assay, mice are in-
fected with a high number (up to 600) of S. mansoni
cercariae. Adult S. mansoni are obtained by portal
perfusion of mice after 40 days post-infection (Yolles
et al. 1947; Smithers and Terry, 1965). 3–4 week old
worms might also be used for in vitro studies (Hobbs
et al. 1993) including drug sensitivity assays, as
juvenile worms might show diﬀerences with regard
to drug sensitivity when compared to larvae and adult
worms. Following several washing steps, worms are
incubated for example in DMEM, RPMI 1640 or
HBSS supplemented with foetal calf serum, peni-
cillin and streptomycin (Ramirez et al. 2007; Xiao
et al. 2007). Schistosomes survive in a range of
In vivo
In vitro
Newly
transformed
schistosomula
in vitro
In vivo
In vitro
Rodent host
Adult schistosomes
Egg
Miracidium
Cercariae
Biomphalaria glabrata
Juvenile
schistosomes
~3 weeks
~4 weeks
Fig. 2. Life cycle of S. mansoni highlighting collection points for in vitro and in vivo chemotherapeutic studies.
Maturation of parasite occurs within ﬁnal host (red arrows).
J. Keiser 592
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182009991739
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:55:12, subject to the Cambridge Core terms of use, available at
Table 1. In vitro drug screening: techniques employed, culture conditions and evaluation of juvenile and adult S. mansoni, F. hepatica and E. caproni assays
Trematode In vitro assays Techniques employed Culture media Key issues Evaluation of assay
Schistosoma
mansoni
Newly
transformed
schistosomula
Mechanical or chemical
transformation
of cercariae
Diﬀerent media possible, e.g.
Bash, MEM, DMEM, TC
199 supplemented with
penicillin and streptomycin
(and foetal calf serum)
Cost-eﬀective and ethical as
large numbers of schistosomula
can be obtained and no animals
needed.
Diﬀerences in drug sensitivity
between schistosomula and
adult worms?
Microscopic assessment of
motility (viability score),
morphology and death of
worms. SEM and TEM
studies.
Schistosomula
(juvenile
worms)
Juvenile worms collected
from lungs of highly
infected mice
(infected with 400–600
cercariae)
Diﬀerent media possible,
e.g.DMEM, RPMI 1640 or
Hanks’ balanced salt solution
supplemented with foetal calf
serum, penicillin and
streptomycin
Rarely used in
chemotherapeutic studies.
Juvenile
schistosomes
(3–4 week old)
Perfusion of the portal
venous system of highly
infected mice (infected
with 400–600 cercariae)
Need of animals.
Drug sensitivity assessed on
target parasite.
Microscopic assessment of
motility (viability score),
morphology and death of
worms, inability to reduce
the tetrazolium, MTT. SEM
and TEM studies.
Adult
schistosomes
Fasciola hepatica Newly excysted
juveniles
Excystation of
metacercariae
RPMI 1640 supplemented with
antibiotics (and serum or red
blood cells)
Cost-eﬀective and ethical as
large numbers of newly
excysted juveniles can be
obtained and no animals
needed.
Diﬀerences in drug sensitivity
between newly excysted
juveniles and adult worms
demonstrated.
Microscopic assessment of
motility, morphology and
death of worms, inability to
reduce the tetrazolium, MTT.
SEM and TEM studies.
Juvenile worms Collection of worms from
rat or sheep livers
NCTC 135 or RPMI 1640
supplemented with antibiotics
(and serum or red blood cells)
Need of animals. Drug
sensitivity assessed on target
parasite.
Microscopic assessment of
motility (viability score),
morphology and death of
worms. SEM and TEM
studies.
Adult worms Collection of worms from
the bile ducts of rats or
sheep
NCTC 135 or RPMI 1640
supplemented with antibiotics
(and serum or red blood cells)
Need of animals. Drug
sensitivity assessed on target
parasite.
Echinostoma
caproni
Juvenile worms Excystation of
metacercariae
NCTC 135 supplemented with
antibiotics and serum or egg
yolk
Cost eﬀective and ethical as large
numbers of newly excysted
juveniles can be obtained and
no animals needed.
Microscopic assessment of
motility (viability score),
morphology and death of
worms. SEM and TEM
studies.Adult
echinostomes
Collection of worms from
the intestine of highly
infected mice (up to 300
metacercariae)
RPMI 1640 supplemented with
antibiotics and glucose
Need of animals.
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supplemented tissue culture media for periods ran-
ging from 3–120 days (Smyth and Halton, 1983).
Test drugs at various concentrations (5 mg/ml is the
standard concentration in the primary screen at
WHO-TDR screening centers (Ramirez et al. 2007))
are added to each culture well containing 6–10
worms. Worms are examined under a dissecting
microscope at diﬀerent time points (e.g. 24, 48 and
72 h). Control schistosomes are incubated in the
presence of the highest concentration of solvent used.
Drug eﬀects are commonly evidenced by phenotypic
changes (motility and morphological changes and
death) using an inverted microscope as described
above. Markers such as MTT formazan have also
been used to evaluate the viability of adult schisto-
somes (Oliveira et al. 2004). For more thorough
studies on the eﬀects of antischistosomal drugs, de-
tailed surface features of treated and untreated
specimensmight be investigated bymeans of SEMas
the tegument of trematodes is a highly susceptible
site of damage following drug treatment (Manneck
et al. 2009). For example, in Fig. 4b the male tegu-
ment is depicted. Fig. 4c shows the tegument of a
male S. mansoni following drug treatment: 72 h post
incubation with 100 mg/ml praziquantel blebbing
was observed.
S. mansoni in vivo model
The mouse is the most commonly used mammalian
host for experimental studies with S. mansoni
(Table 2, Fig. 2). Though a diﬀerence has been ob-
served regarding the percentage of cercariae that
mature in diﬀerent mouse strains, most mice strains
tested were susceptible to an infection with S. man-
soni (Lewis, 2001). 129/Ola and WEHI 129J mice
are two examples of non-permissive hosts (Elsaghier
et al. 1989). Hamsters (Xiao, et al. 2007), gerbils
(Chisty et al. 2002), rabbits (Kasilima et al. 2004) or
primates (Webbe et al. 1981) have also been used to
study S. mansoni in vivo. The rat is only a semi-
permissive host (Cioli et al. 1977) and therefore un-
likely to be suitable for the present purpose.
Animals are infected either by skin penetration,
usually through the tail or shaved abdominal skin or
via subcutaneous or intraperitonal injection of cer-
cariae (Lewis, 2001). For chemotherapeutic studies it
is important to compare the number of schistosomes
in treated and untreated control animals, which is
usually done after schistosomes have matured (6 to
8 weeks after infection).
Schistosomes are obtained and counted either via
perfusion of the portal venous system (Yolles et al.
Fig. 3. Schistosoma mansoni – (a): light microscopic (LM) image of newly transformed control schistosomula. (b) SEM
image of newly transformed control schistosomula. (c) LM image of newly transformed schistosomula incubated for
72 h in the presence of 100 mg/ml praziquantel (d) SEM image of newly transformed schistosomula incubated for 72 h
in the presence of 100 mg/ml praziquantel.
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1947; Lewis, 2001) or examining the mesenteric
veins and the liver for the presence of schistosomes
(Xiao et al. 2007). In the latter case, the liver and
the small and large intestines are removed from the
animal. The liver is placed into a 20r20 cm trans-
parent plastic folder, compressed between 2 glass
plates and the parenchyma is examined under a
stereoscopic microscope. In addition, the mesenteric
veins are systematically examined using a stereo-
scopic microscope. All schisosomes present in the
liver and mesenteric veins are sexed and counted
(Xiao et al. 2007).
To revisit our example of praziquantel, the current
drug of choice, the in vivo antischistosomal proper-
ties of this drug have been well studied in the
S. mansoni-mouse model. For example, a single
300 mg/kg oral dose of praziquantel resulted in a
worm burden reduction of 81% (Xiao et al. 1999).
FASCIOLA HEPATICA
Fascioliasis is a major public health problem and
an economically serious disease of livestock. Novel
treatment options are of high priority as resistance to
triclabendazole, the drug of choice in human and
animal medicine, is spreading (Keiser et al. 2005;
Fairweather, 2009). In addition, triclabendazole is
licensed in only 4 countries (Keiser, et al. 2005).
Chemotherapeutic studies have been undertaken
with both F. hepatica and F. gigantica, although the
former species has been more extensively studied.
The life cycle of Fasciola spp. is maintained at
several research laboratories, universities and private
companies (Fig. 1), where metacercariae (diﬀerent
triclabendazole-resistant and -sensitive isolates) can
be obtained or purchased. Brieﬂy, the lymnaeid
snails Galba spp. and Fossaria spp. mainly act as
intermediate hosts (Mas-Coma et al. 2007). Infection
in humans and animals occur through the ingestion
of metacercariae attached to water vegetables or in
contaminated water (Keiser et al. 2005; Mas-Coma
et al. 2007; Keiser and Utzinger, 2009). In exper-
imental infections laboratory animals are exposed to
metacercariae by stomach tube or oesophageal intu-
bation, while a gelatin bolus or capsule containing the
metacercariae are often used to infect sheep (Clery
et al. 1995). In the intestine the ﬂuke excysts (newly
excysted juvenile), penetrates the gut wall and enters
the body cavity. After wandering over the viscera the
juvenile ﬂukes reach the liver. For several weeks
the juvenile ﬂukes burrow through the liver causing
hemorrhage, tissue destruction and destruction of
the liver cells. Approximately 8 weeks after infection
F. hepatica reach the bile ducts, where they continue
to grow and develop into adults, reaching full size
by 12–14 weeks after infection (Anderson and
Fairweather, 1995; Fairweather et al. 1999). Due to
the massive damage of the migrating juvenile stages
of the parasite, an ideal fasciolicidal drug should be
active against both parasite stages, as is triclabenda-
zole (Keiser et al. 2005; Fairweather, 2009).
F. hepatica in vitro assays
Newly encysted juveniles, young and adult worms
can be cultured in vitro (Fig. 5, Table 1). An assay
based on newly excysted juveniles oﬀers the advan-
tage that, as for the schistosomula assay described
above, a mammalian host is not required. Meta-
carcariae excyst when exposed to appropriate stimuli
(Dixon, 1966). Commonly used SOPs include ex-
posure of metacercariae to an activation medium
followed by incubation in an emergence medium.
For example, the following protocol has been de-
scribed byMcGonigle and colleagues: metacercariae
are excysted by incubation in 0.5% sodium hypo-
chlorite for 20 min prior to centrifugation (2000 g for
2 min), washing in distilled water and incubation in
0.5% sodium bicarbonate, 0.4% sodium chloride,
0.2% sodium tauroglycholate, 0.07% concentrated
HCl and 0.006% l-cysteine for up to 3 h at 37 xC
(McGonigle et al. 2008). Excysted juveniles are
maintained in nutritive culture medium, such as
Fig. 4. Schistosoma mansoni – SEM observations.
(a) dorsal male tegument and (b) blebbing (b) observed
on the dorsal male tegument following incubation with
100 mg/ml praziquantel for 72 h.
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RPMI 1640, supplemented with penicillin and
streptomycin and possibly serum or red blood cells
(Ibarra and Jenkins, 1984). In vitro assays based on
newly excysted ﬂukes have been used to study the
fasciolicidal activities of investigational compounds;
for example, 20 plant extracts were recently eval-
uated using this parasite stage (Vera-Montenegro
et al. 2008). Nonetheless, newly excysted ﬂukes
might have diﬀerent drug sensitivities when com-
pared to juvenile and adult ﬂukes: a study which
compared the fasciolicidal activity of known fas-
ciolicides demonstrated that newly excysted ﬂukes
were unaﬀected by most of these compounds (Ibarra
and Jenkins, 1984).
Assays based on juvenile or adultFasciola aremore
often used to study fasciolicidal properties of in-
vestigational drugs in vitro. The main disadvantages
of these assays are that only few ﬂukes can be re-
covered from the laboratory rat, which is the main
rodent host. Rats tolerate an infective dose of 20–30
metacercariae, yielding between 2 and 13 mature
ﬂukes (Chapman andMitchell, 1982). In addition, as
mentioned above, Fasciola spp. grow for 8–12 weeks
until they are fully mature. Hence, these assays are
expensive and time consuming. Another possibility
to obtain parasite material in a more eﬃcient and
less costly manner in endemic countries is to collect
worms from animals slaughtered in abattoirs
(Shalaby et al. 2009). Juvenile or adult Fasciola are
incubated in the presence of RPMI 1640 or NTCT
135, supplemented with antibiotics and the in-
vestigational drug (Anderson and Fairweather, 1995;
Keiser et al. 2006). Though supplementation of the
medium with serum is recommended for long term
culture of Fasciola spp. (longer than 4 days), serum
substitution may not be advised for Fasciola drug
activity studies, asmanydrugs bind strongly to serum
proteins (Jenkins et al. 1987).Fasciolicidal drugs such
as rafoxanide or bithionol showed a decreased activity
in vitro in the presence of serum compared to ser-
umlessmedium (Jenkins et al. 1987). The presence of
bile in the incubationmedium has also been shown to
inﬂuence the uptake pattern of fasciolicidal drugs,
such as triclabendazole or albendazole (Alvarez et al.
2004). As described above for the schistosomes, fas-
ciolicidal properties are examined documenting mo-
tility, morphological changes and death. To my
knowledge metabolic markers have not been used in
Fasciola drug sensitivity assays. Drug eﬀects have
also been well documented using SEM and trans-
mission electron microscopy (TEM) (Anderson and
Fairweather, 1995; McConville et al. 2006; Keiser
and Morson, 2008). For example, Fig. 6a shows a
SEM image of the anterior region of a F. hepatica.
We have recently described that the semi-synthetic
artemisinin derivatives artemether and artesunate,
which are essential components of malaria therapy
(White, 2008) and synthetic derivatives possess a
broad range of trematodicidal activities (Keiser andT
ab
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Utzinger, 2007; Utzinger et al. 2007). Fig. 6b depicts
the head region of aFasciolaﬂuke48 hpost-treatment
with a single 200 mg/kg oral dose of artemether, re-
vealing blebbing, sloughing and roughening of the
tegumental surface (Keiser and Morson, 2008).
F. hepatica in vivo assays
F. hepatica can be grown in diﬀerent laboratory ani-
mals but, as mentioned above, the rat is the most
commonly used rodent to study F. hepatica in vivo
(Fig. 5, Table 2). No signiﬁcant diﬀerence was ob-
served between diﬀerent rats strains infected with
F. hepatica with regard to worm burden (Chapman
and Mitchell, 1982). Rats, commonly infected with
20–30 metacercariae, harbour between 2–13 adult
ﬂukes (Chapman and Mitchell, 1982). The labora-
tory mouse is not a suitable model to grow adult
F. hepatica, as mortality of mice is high and the ﬂukes
do not fully develop in this model (Chapman and
Mitchell,1982; Smyth and Halton, 1983). The in-
fectivity of F. giganticawas found to be low inWistar
rats (Itagaki et al. 1994). Rabbits, the rat-like ham-
ster, Tscherskia triton, and sheep have also been used
for studies of experimental fascioliasis (Terasaki et al.
2003; McConville et al. 2009).
In chemotherapeutic studies, groups of rats or
sheep, which had been experimentally infected with
F. hepatica for 3–5 weeks (juvenile infection) and
8–12 weeks (adult infection) or sheep harbouring a
Fig. 6. Fasciola hepatica – SEM observations. (a) anterior region of an adult F. hepatica recovered from a rat (OS: oral
sucker, VS: ventral sucker). (b) Blebbing (b) and sloughing (s) visible near the ventral sucker (VS) on a F. hepatica
recovered from a rat 48 h post-treatment with a single oral dose of 200 mg/kg artemether.
3 weeks
Newly
excysted
juveniles
in vitro
In vivo
In vitro
Rodent host
Adult Fasciola
Egg
Miracidium
Metacercariae
Galba truncatula
5 weeks
Juvenile
Fasciola
In vivo
In vitro
Fig. 5. Life cycle of F. hepatica highlighting collection points for in vitro and in vivo chemotherapeutic studies.
Maturation of parasite occurs within ﬁnal host (red arrows).
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natural infection are treated with the investigational
drugs and the numbers of ﬂukes present in the livers
and bile ducts are counted several weeks post treat-
ment. Groups of untreated animals serve as controls
(Keiser et al. 2006, 2008; McConville et al. 2009).
Besides the eﬀect of the drug on the Fasciola worm
burden, the egg count reduction and the eﬀect of the
drug on the morphology, tegument or intestinal
structures are studied (McKinstry et al. 2003; Keiser
and Morson, 2008; McConville et al. 2009).
Revisiting the artemisinins, the fasciolicidal pro-
perties of artemether were thoroughly studied in
F. hepatica-infected rats (both a triclabendazole-
resistant and -sensitive isolate) and sheep harbouring
a natural F. hepatica infection: single oral artemether
at 200 mg/kg achieved a complete cure in rats (Keiser
et al. 2006, 2007), while a worm burden reduction
of 91% was recorded in sheep following a single in-
tramuscular administration of 160 mg/kg artemether
(Keiser et al. 2008).
ECHINOSTOMA CAPRONI
The third example is the intestinal ﬂuke E. caproni,
which has been widely used as an experimental
model in diﬀerent areas of research, as its life cycle is
easy to maintain in the laboratory (Fried and
Huﬀman, 1996). Laboratories, which maintain
this life cycle are depicted in Fig. 1. Echinostomes
invade domestic animals, wildlife or humans (Toledo
and Fried, 2005). The rodent and the avian ﬂuke
E. caproni cycles between B. glabrata snails and
laboratory mice (Fig. 7) (Fried and Huﬀman, 1996).
Brieﬂy, mice are infected orally with 25–50 meta-
cercariae, though up to 300 metacercariae are toler-
ated (Platt, 2009). An adult infection is established
y2 weeks after infection. For life cycle maintenance,
eggs can be removed either directly from the worms
collected from mice intestines or faeces. After em-
bryonation of eggs for about 14–17 days at room
temperature miracidia develop. Biomphalaria glab-
rata are exposed to fully developed eggs or miracidia
(Idris and Fried, 1996). Four to six weeks after in-
fection of snails, most snails in the aquarium contain
hundreds of metacercariae in the pericardial kidney
region (Fried and Huﬀman, 1996).
E. caproni in vitro assay
Encysted metacercariae of E. caproni can be excysted
in a trypsin-bile salts-cysteine medium (Table 1)
(Saxton et al. 2008; Fried and Peoples, 2009).
Excysted larvae have been mainly used in in vitro
culture studies and might also prove useful for che-
motherapeutic, biological or physiological studies as
reviewed elsewhere (Fried, 1994). Excysted larvae
are cultured in a deﬁned medium such as NCTC 135
supplemented with antibiotics and diﬀerent types of
natural products such as serum, egg yolk or mucus
(Fried, 2000).
Several studies have examined the echinostomici-
dal properties of investigational drugs using adult
echinostomes in vitro (Leger et al. 1973; Leger and
Notteghem, 1975; Keiser et al. 2006). Though adult
echinostomesmaintained in vitro deteriorate quickly,
possibly due to microbial contamination and/or
Rodent host 10–14
days
Adult echinostomes
In vivo
In vitro
Excysted
larvae
in vitro
Egg
Miracidium
Metacercariae
Biomphalaria glabrata
Fig. 7. Life cycle of E. caproni highlighting collection points for in vitro and in vivo chemotherapeutic studies.
Maturation of parasite occurs within ﬁnal host (red arrow).
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worm autolysis (Fried, 2000), echinostomes can be
maintained in nutritive media such as RPMI 1640
ideally supplemented with additional glucose (e.g.
1%) for several days (Leger et al. 1973). As described
above worms incubated in the presence of drugs are
analyzed for occurrence of death, motility disturb-
ances or morphological changes.
E. caproni in vivo assay
While there is a high degree of compatibility between
E. caproni and mice and hamsters, rats show a low
degree of compatibility with E. caproni (Toledo and
Fried, 2005). E. caproni can survive for more than 20
weeks in mice and hamsters (Toledo and Fried,
2005). The laboratory mouse is most commonly
used to study E. caproni in vivo (Table 2). As adult
infections are established already by 10–14 d after
infection, this model allows for quicker patent in-
fections in the deﬁnitive hosts than the F. hepatica or
S. mansoni assays described above. Hence, results are
obtained rapidly and cost-eﬀectively in the E. cap-
roni-mouse model. In vivo studies in Echinostoma
spp. infectedmice, with various test compounds such
as the benzimidazoles, praziquantel, the artemisinins
or tribendimidine against echinostomes in mice have
been summarized recently (Saric et al. 2009). For
example, E. caproni-infected mice were cured fol-
lowing a single oral dose of 700 mg/kg artesunate
(Keiser et al. 2006). In Fig. 8a the head region of an
untreated E. caproni is depicted. Four h after treat-
ment with a single 700 mg/kg oral dose of artesunate
eruption and sloughing was observed on the ventral
surface of an E. caproni ﬂuke (Fig. 8b) (Keiser et al.
2006).
CONCLUSION
Schistosomiasis and food-borne trematodiases are
chronic parasitic diseases aﬀectingmillions of people,
mostly in the developing world. The number of
drugs available to treat these diseases is surprisingly
small and preliminary reports of resistance in the
ﬁeld and laboratory highlight the need to develop
new trematodicidal drugs (Colley et al. 2001; Caﬀrey
2007;Keiser andUtzinger, 2009). In vitro and in vivo
whole parasite screens represent essential compo-
nents of the trematodicidal drug discovery cascade in
particular as molecular-based target drug screening
approaches are still very limited. Nonetheless, pub-
lications of latest draft genome sequences e.g. for
schistosomes (Berriman et al. 2009; Liu et al. 2009)
will provide new insights into the biology of trema-
todes and oﬀer an opportunity for identiﬁcation
of potential drug targets. For example, 71,028 com-
pounds were recently screened for thioredoxin/
glutathione reductase and peroxiredoxin activity,
principal components of the defence system of
schistosomes (Cioli et al. 2008; Simeonov et al.
2008). Eﬀorts to enter novel molecular targets in the
trematodicidal drug-discovery process should go
hand-in-hand with an improvement of existing
whole organism screens. Validated, robust, high
throughput in vitro systems are needed to boost
the discovery pipeline for these diseases (Colley
et al. 2001). Diﬃculties still need to be overcome
in the basic cultivation of trematodes. In addition,
phenotypic assessment of treated parasites is still
the method of choice in in vitro drug screens
and the development of simple readouts that are
amenable to automated analysis (e.g. calorimetric
analysis, viability markers) would be a great step
forward.
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